Condition: Cystic Fibrosis · Lung Diseases · Sponsor: University of British Columbia
Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.
This description comes directly from the study's public registry record.
Satvir S Dhillon, MSc · 6048068835 · satvir.dhillon@hli.ubc.ca
Jordan Guenette, PhD · 16048068835 · jordan.guenette@hli.ubc.ca
Always discuss trial participation with your own doctor first.
| UBC Centre for Heart Lung Innovation, St. Paul's Hospital | Vancouver, British Columbia, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05279040